Q2 FY2026 EarningsQ2 FY26 performance significantly beat consensus across all key profitability metrics, with GAAP EPS of $0.16 vs. $0.04 expected (+300%) and total revenue of $56.5M slightly exceeding the $53M estimate. The bottom-line outperformance was driven by a substantial reduction in interest expense following debt elimination and stronger-than-expected product demand for NERLYNX. Management raised FY26 total revenue guidance to $224M–$231M and net income to $17M–$20M, signaling sustained commercial momentum despite rising R&D investment for the alisertib pipeline.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Puma BioTech(PBYI) the Revenue is 56.5 M (+7.82%), Beat estimate;the EBIT is 7.6 M (--%), Beat estimate;the EPS is 0.16 (+33.33%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.06B7.82%
0.05B1.15%
+0.00B6.67%
EBITExceed expectations
0.01B--
0.00B--
+0.01B--%
EPSExceed expectations
0.1633.33%
0.0466.67%
+0.1200100.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf